



NEWS RELEASE

Akaal Pharma to Attend 35th J. P. Morgan Healthcare Conference

MELBOURNE, Australia and SAN DIEGO, USA, Dec 7, 2016. Akaal Pharma Pty Ltd, announced today that Dale Dhanoa, CEO of Akaal Pharma will be attending the 35th J. P. Morgan Healthcare Conference to be held on Jan 9-12, 2017, at the Westin St. Francis Hotel, San Francisco, California, USA. Akaal Pharma's senior management is interested and engaged in its business and corporate development including capital raise and drug development partnerships with pharmaceutical and biotech companies for its future dynamic growth.

Please contact us via email (bd@akaalpharma.com) or info@akaalpharma.com or at the phone numbers +1 (858) 925-4555 (USA) or Tel. +61 3 9479 2584 (Australia) to explore capital investments and drug development partnering opportunities during and/or prior to the 35th J. P. Morgan Healthcare Conference (Jan 9-12, 2017).

About Akaal

Akaal Pharma is a clinical-stage drug discovery and development company focused on advancing the clinical development of its internally discovered topical and oral small molecule drug candidates for treating inflammatory and immune diseases specifically psoriasis, atopic dermatitis, pain, multiple sclerosis, ulcerative colitis and others serious diseases. For more information, visit www.akaalpharma.com.

Psoriasis and Atopic Dermatitis Programs

Akaal Pharma's leading drug candidate AKP-11 is a novel, potent and highly selective sphingosine 1-phosphate receptor-1 (S1P₁) modulator undergoing clinical development for the treatment of psoriasis, atopic dermatitis and other serious inflammatory and immune diseases with unmet medical need. AKP-11 has successfully its Phase 1 clinical trial in which it demonstrated excellent safety, tolerability and significant efficacy for treating Psoriasis. Currently it is undergoing several other clinical trials in dermatology.

Contact

Dale Dhanoa, Ph.D.,
Chief Executive Officer
Akaal Pharma Pty Ltd.
Thomas Cherry Building - 301E
La Trobe University
Bundoora, VIC-3086
Australia
Direct: +1 858 925-4555 (USA)
Tel. +61 3 9479 2584 (Australia)
info@akaalpharma.com
bd@akaalpharma.com